Aprea Therapeutics (NASDAQ:APRE) stockholders approved all proposals presented at the company’s 2026 annual meeting, including authorization for the board of directors to implement a reverse stock split within a specified range, according to remarks made during the virtual meeting.
The annual meeting was called to order by Dr. Oren Gilad, Aprea’s President and Chief Executive Officer, who presided as chairman of the meeting. Gilad said the company chose a virtual format to allow stockholders to attend from anywhere. John Hamill, Senior Vice President and Chief Financial Officer, served as secretary of the meeting.
Reverse Stock Split Authorization Approved
The most notable proposal approved by stockholders was an amendment to Aprea’s amended and restated certificate of incorporation authorizing the board to effect a reverse stock split of the company’s common stock.
Under the approved proposal, the board may implement a reverse split at a ratio of not less than 1-for-3 and not more than 1-for-8. The exact ratio will be determined by the board in its sole discretion. Fractional shares would be rounded up to the nearest whole share, and the reverse split would not reduce the authorized number of shares of common stock.
The proposal also gives the board discretion over whether to proceed with the reverse split and, if so, when it would take effect.
Directors Elected to Three-Year Terms
Stockholders also elected three Class directors to serve three-year terms expiring at the 2029 annual meeting of stockholders. The nominees elected were Marc Duey, Richard Peters and Bernd Seizinger, each of whom was already serving as a director of the company.
Gilad also noted that Aprea’s directors were in virtual attendance. In addition to Gilad, Duey, Peters and Seizinger, the directors identified at the meeting included Jack Henneman, Mike Grissinger, Gabriela Gruia, Rif Pamukcu and Jean-Pierre Bizzari. Peters was identified as chairman of the board.
Auditor Ratification and Advisory Votes
Stockholders ratified the appointment of EisnerAmper LLP as Aprea’s independent registered public accounting firm for the 2026 fiscal year. Gilad said EisnerAmper was represented at the meeting by Mark Palu, who was available to answer stockholder questions directed to the auditors.
In addition, stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers. They also voted for future advisory votes on named executive officer compensation to be held annually.
A proposal to approve adjournment of the annual meeting, if necessary, to solicit additional proxies in the event there were insufficient votes for the reverse stock split proposal, was also approved.
No Stockholder Questions Submitted
During the meeting, stockholders were given the opportunity to submit questions regarding matters to be voted on, as well as general company concerns after formal business concluded. Meeting officials said no questions were submitted on the voting items, and Gilad later said there were no questions for the Q&A session.
The preliminary vote report was provided during the meeting. The company said final voting results would be reported in a Form 8-K to be filed within four business days. Gilad then adjourned the meeting.
About Aprea Therapeutics (NASDAQ:APRE)
Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.
Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.
